{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:48Z","timestamp":1791389928483,"version":"4.3.3"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1053\/ctrv.2001.0243","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T13:54:50Z","timestamp":1032443690000},"page":"327-337","source":"Crossref","is-referenced-by-count":30,"title":["Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines"],"prefix":"10.1053","volume":"27","author":[{"given":"M","family":"Ronghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.A","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P","family":"Lowis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J","family":"Estlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/ctrv.2001.0243_RF1","first-page":"535","article-title":"L-asparaginase, vincristine and prednisolone for induction of first remission in acute lymphocytic leukaemia","volume":"37","author":"Ortega","year":"1977","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF2","first-page":"425","article-title":"Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukaemia: clinical results","volume":"51","author":"Sallan","year":"1978","journal-title":"Blood"},{"key":"10.1053\/ctrv.2001.0243_RF3","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukaemia patients. Results and conclusions of the multi-centre trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.1053\/ctrv.2001.0243_RF4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(95)90164-7","article-title":"Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X","volume":"345","author":"Chessells","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/ctrv.2001.0243_RF5","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B","article-title":"Early response to therapy and outcome in childhood acute lymphoblastic leukaemia","volume":"80","author":"Gaynon","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2001.0243_RF6","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood.V86.4.1292.bloodjournal8641292","article-title":"Persistence of circulating blasts after 1 week of multi-agent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukaemia","volume":"86","author":"Gajjar","year":"1995","journal-title":"Blood"},{"key":"10.1053\/ctrv.2001.0243_RF7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1365-2141.1997.1792996.x","article-title":"A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse","volume":"98","author":"Jacquy","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/ctrv.2001.0243_RF8","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/ctrv.2001.0243_RF9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.leu.2401129","article-title":"Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukaemia \u2013 implications for treatment of infants","volume":"12","author":"Pierters","year":"1998","journal-title":"Leukaemia"},{"key":"10.1053\/ctrv.2001.0243_RF10","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","article-title":"In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukaemia","volume":"90","author":"Kaspers","year":"1997","journal-title":"Blood"},{"key":"10.1053\/ctrv.2001.0243_RF11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-2008-1043794","volume":"99","author":"Janka-Schaub","year":"1999","journal-title":"Klin Padiatr"},{"key":"10.1053\/ctrv.2001.0243_RF12","first-page":"263","article-title":"Antimicrotubule agents","author":"Rowinsky","year":"1996"},{"key":"10.1053\/ctrv.2001.0243_RF13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0006-2952(96)00041-X","article-title":"Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukaemic T-lymphocytes","volume":"51","author":"da Silva","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF00695987","article-title":"Relationship between tumour cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of innoculum effects","volume":"31","author":"Kobayashi","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0006-2952(97)00615-1","article-title":"Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukaemia cells","volume":"55","author":"Kobayashi","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF16","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1016\/0006-2952(88)90085-8","article-title":"Relationships between tumour responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumour xenografts","volume":"37","author":"Horton","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF17","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861","article-title":"In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukemia","volume":"86","author":"Klumper","year":"1995","journal-title":"Blood"},{"key":"10.1053\/ctrv.2001.0243_RF18","first-page":"665","article-title":"Apoptosis and steroid hormones","volume":"8","author":"Thompson","year":"1994","journal-title":"Mol Endocrinol"},{"key":"10.1053\/ctrv.2001.0243_RF19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4049\/jimmunol.133.1.273","article-title":"Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA","volume":"133","author":"Arya","year":"1984","journal-title":"J Immunol"},{"key":"10.1053\/ctrv.2001.0243_RF20","doi-asserted-by":"crossref","first-page":"18306","DOI":"10.1016\/S0021-9258(17)46845-1","article-title":"Suppression of c-myc is a critical step in glucocorticoid-induced human leukaemic cell lysis","volume":"268","author":"Thulasi","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1053\/ctrv.2001.0243_RF21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(90)90395-U","article-title":"Antitumor promotion and anti-inflammation: Down-modulation of AP-1 (Fos\/Jun) activity by glucocorticoid hormone","volume":"62","author":"Jonat","year":"1990","journal-title":"Cell"},{"key":"10.1053\/ctrv.2001.0243_RF22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/383726a0","article-title":"Functional interactions between Stat5 and the glucocorticoid receptor","volume":"383","author":"Stocklin","year":"1996","journal-title":"Nature"},{"key":"10.1053\/ctrv.2001.0243_RF23","first-page":"3785","article-title":"Characterisation of a glucocorticoid-sensitive human lymphoid cell line","volume":"37","author":"Norman","year":"1977","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/bjc.1995.181","article-title":"Induction of apoptosis by anti-cancer drugs with disparate modes of action: kinetics of cell death and changes in c-myc expression","volume":"71","author":"Wood","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2001.0243_RF25","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.1996.14.8.2370","article-title":"Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia","volume":"14","author":"Ito","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF26","first-page":"6482","article-title":"Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a pediatric oncology group study","volume":"45","author":"Quddus","year":"1985","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF27","first-page":"1378","article-title":"Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukaemic T cells","volume":"59","author":"Ramdas","year":"1999","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF28","first-page":"5033","article-title":"Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression","volume":"56","author":"Geley","year":"1996","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/(SICI)1096-911X(199608)27:2<114::AID-MPO8>3.0.CO;2-I","article-title":"Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia","volume":"27","author":"Kaspers","year":"1996","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0145-2126(83)90068-1","article-title":"Response of recurrent acute lymphoblastic leukemia to GC: serial studies of receptor content, in vivo cytokinetic changes and clinical responses","volume":"7","author":"Pui","year":"1983","journal-title":"Leukemia Res"},{"key":"10.1053\/ctrv.2001.0243_RF31","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood.V82.8.2304.2304","article-title":"High glucocorticoid receptor content of leukemic blasts is a favourable prognostic factor in childhood acute lymphoblastic leukemia","volume":"82","author":"Kato","year":"1993","journal-title":"Blood"},{"key":"10.1053\/ctrv.2001.0243_RF32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"M\u00fcller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/ctrv.2001.0243_RF33","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.leu.2400834","article-title":"Cell cycle arrest and apoptosis of leukaemia cells induced by L-asparaginase","volume":"11","author":"Ueno","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/ctrv.2001.0243_RF34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ijc.2910500427","article-title":"Pre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity","volume":"50","author":"Shimizu","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1053\/ctrv.2001.0243_RF35","first-page":"294","article-title":"Biochemical characterization of U937 cells resistant to L-asparaginase: The role of asparagine synthase","volume":"3","author":"Kiriyama","year":"1989","journal-title":"Leukemia"},{"key":"10.1053\/ctrv.2001.0243_RF36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0005-2787(67)90569-2","article-title":"Differences in the production of L-asparagine in asparaginase-sensitive and resistant lymphoma cells","volume":"138","author":"Broome","year":"1967","journal-title":"Biochim Biophys Acta"},{"key":"10.1053\/ctrv.2001.0243_RF37","doi-asserted-by":"crossref","first-page":"C1691","DOI":"10.1152\/ajpcell.1997.272.5.C1691","article-title":"Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukaemia cells","volume":"272","author":"Hutson","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1053\/ctrv.2001.0243_RF38","first-page":"602","article-title":"Asparaginase (ASNase) induced cytotoxicity depends on the p53 status of the cells","volume":"39","author":"Fu","year":"1998","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF39","first-page":"602","article-title":"Apoptosis induced by antimetabolites, taxanes or asparaginases in vitro depends on the p53 status of the leukaemic cells","volume":"39","author":"Nandy","year":"1998","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF40","first-page":"4363","article-title":"In vitro and in vivo killing of acute lymphoblastic leukaemia cells by L-asparaginase","volume":"49","author":"Asselin","year":"1989","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0140-6736(91)91029-T","article-title":"Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia","volume":"338","author":"Pieters","year":"1991","journal-title":"Lancet"},{"key":"10.1053\/ctrv.2001.0243_RF42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00043426-199901000-00003","article-title":"Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia","volume":"21","author":"Asselin","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF43","first-page":"409","article-title":"Anthracyclines and anthracenediones","author":"Doroshow","year":"1996"},{"key":"10.1053\/ctrv.2001.0243_RF44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00262582","article-title":"Leukaemic cell and plasma daunomycin concentrations after bolus and 72 hour infusion","volume":"20","author":"Speth","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00262581","article-title":"Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukaemia patients","volume":"20","author":"Speth","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF46","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.1988.6.5.802","article-title":"Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeliod leukaemia","volume":"6","author":"Kokenberg","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF47","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.1996.14.3.911","article-title":"High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukaemia: Results of protocol ALL VI form the Dutch Childhood Leukaemia Study Group","volume":"14","author":"Veerman","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002800050968","article-title":"Vincristine pharmacokinetics after repetitive dosing in children","volume":"44","author":"Gidding","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mpo.2950240405","article-title":"Vincristine disposition in children with acute lymphoblastic leukaemia","volume":"24","author":"de Graf","year":"1995","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0022-3476(94)70027-3","article-title":"Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukaemia","volume":"125","author":"Crom","year":"1994","journal-title":"J Pediatr"},{"key":"10.1053\/ctrv.2001.0243_RF51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00273423","article-title":"Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity","volume":"22","author":"Pinkerton","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0022-3476(78)80529-0","article-title":"Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity","volume":"93","author":"Green","year":"1978","journal-title":"J Pediatr"},{"key":"10.1053\/ctrv.2001.0243_RF53","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/clpt.1990.167","article-title":"Monitoring glucocorticoid therapy: A pharmacokinetic approach","volume":"48","author":"Hill","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/ctrv.2001.0243_RF54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF00435843","article-title":"Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia","volume":"23","author":"Choonara","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF55","first-page":"301","article-title":"Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data","volume":"64","author":"Bannwarth","year":"1997","journal-title":"Revue du Rhumatisme (English Edition)"},{"key":"10.1053\/ctrv.2001.0243_RF56","first-page":"329","article-title":"Pharmacokinetics of dexamethasone in children","volume":"3","author":"Richter","year":"1983","journal-title":"Pediatric Pharmacol"},{"key":"10.1053\/ctrv.2001.0243_RF57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.1987.5.2.202","article-title":"Differences in cerebrospinal fluid penetration of: possible relationship to the prevention of meningeal leukemia","volume":"5","author":"Balis","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF58","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32","author":"Boos","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2001.0243_RF59","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1200\/JCO.1997.15.6.2222","volume":"15","author":"Nachman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF60","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"M\u00fcller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/ctrv.2001.0243_RF62","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact on treatment outcome of childhood acute lymphoblastic leukaemia","volume":"18","author":"Woo","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1542\/peds.38.1.82","article-title":"Vincristine in the treatment of acute leukaemia in children","volume":"38","author":"Heyn","year":"1996","journal-title":"Pediatrics"},{"key":"10.1053\/ctrv.2001.0243_RF64","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cpt196673332","article-title":"The role of vincristine in the treatment of childhood acute leukaemia","volume":"7","author":"Karon","year":"1966","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/ctrv.2001.0243_RF65","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(195609\/10)9:5<965::AID-CNCR2820090517>3.0.CO;2-L","article-title":"Prednisolone therapy of acute lymphatic leukemia in children","volume":"9","author":"Hyman","year":"1956","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2001.0243_RF66","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1542\/peds.24.6.1005","article-title":"Prednisolone in childhood leukemia. Comparison of interrupted with continuous therapy","volume":"24","author":"Hyman","year":"1959","journal-title":"Pediatrics"},{"key":"10.1053\/ctrv.2001.0243_RF67","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0022-3476(67)80052-0","article-title":"Prednisolone therapy of acute childhood leukemia: prognosis and duration of response in 330 treated patients","volume":"70","author":"Wolff","year":"1967","journal-title":"J Pediatrics"},{"key":"10.1053\/ctrv.2001.0243_RF68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0002-9343(57)90096-7","article-title":"The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas","volume":"22","author":"Ranney","year":"1957","journal-title":"Am J Med"},{"key":"10.1053\/ctrv.2001.0243_RF69","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/1097-0142(196803)21:3<346::AID-CNCR2820210303>3.0.CO;2-Y","article-title":"Varying prednisolone dosage in remission induction of previously untreated childhood leukemia","volume":"21","author":"Leikin","year":"1968","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2001.0243_RF70","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2001.19.4.1040","article-title":"Improved response with higher corticosteroid dose in children with acute lymphoblastic leukaemia","volume":"19","author":"Schwartz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V92.1.259.413k21_259_266","article-title":"Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro\u2013vivo correlations and cross-resistance to other drugs","volume":"92","author":"Kaspers","year":"1998","journal-title":"Blood"},{"key":"10.1053\/ctrv.2001.0243_RF72","first-page":"66","article-title":"L-asparaginase (L-ASP) in advanced childhood leukemia: comparative trial of drug schedules singly and in combination","volume":"11","author":"Rausen","year":"1970","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF73","first-page":"3893","article-title":"Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: A Report from the Children's Cancer Study Group","volume":"39","author":"Ertel","year":"1979","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2001.0243_RF74","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","article-title":"Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia","volume":"96","author":"Ahlke","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/ctrv.2001.0243_RF75","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/oxfordjournals.annonc.a010722","article-title":"L-asparaginase depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukaemia during subsequent exposures to Erwinia L-asparaginase","volume":"7","author":"Gentili","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF76","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.1999.17.5.1568","article-title":"Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukaemia","volume":"17","author":"Woo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF77","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1200\/JCO.1995.13.2.339","article-title":"Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia","volume":"13","author":"Dibenedetto","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF78","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.1988.6.5.802","article-title":"Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukaemia","volume":"6","author":"Kokenberg","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2001.0243_RF79","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/bjc.1994.301","article-title":"Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia","volume":"70","author":"Galettis","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2001.0243_RF80","first-page":"669a","article-title":"The importance of L-asparaginase in the treatment of acute lymphoblastic leukaemia in children: Results of the EORTC 58881 randomised phase III trial showing greater efficiency of E. coli as compared to Erwinia asparaginase","volume":"88","author":"Otten","year":"1996","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737201902439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737201902439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T05:05:41Z","timestamp":1682139941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737201902439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S0305737201902439"],"URL":"https:\/\/doi.org\/10.1053\/ctrv.2001.0243","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}